Business Wire

HYCM

30.3.2017 10:53:26 CEST | Business Wire | Press release

Share
HYCM Seals European Presence With CySEC Regulation

HYCM, an FCA-regulated global leader in online capital markets trading, has confirmed that its Cyprus-based entity HYCM Europe is licenced and regulated by the Cyprus Securities and Exchange Commission (CySEC). The status is now reflected on the company website.

CySEC is Cyprus’s financial regulator which provides a framework within which the country’s financial services companies are obliged to operate. As a CySEC regulated broker, HYCM must adhere to the strictest financial standards, including capital adequacy requirements, segregation of client funds and transparency of business operations.

An international broker with a strong presence in key markets in Asia, Middle East and the United Kingdom, HYCM is now set to expand its footprint in the European Union, providing traders with the opportunity to benefit from competitive pricing, high execution speed, high levels of financial security and its renowned customer support.

Commenting on the CySEC licence, Stavros Lambouris, CEO, HYCM Europe said, “The CySEC authorisation marks a milestone in our history as part of our plans to expand our global operations. We now have a gateway to the European market, affirming our commitment to our European clients whilst rubber-stamping the company’s position as a global leader”.

HYCM is part of the Henyep Capital Markets Group, an international conglomerate which recently rebranded its UAE operations within the DIFC to unify its offices worldwide and to reflect the broad range of capital markets products on offer to its retail clients. DFSA-regulated Henyep Investment Bank Limited became known as Henyep Capital Markets (DIFC) Ltd as part of its plans for growth in the region, particularly within the UAE.

The latest move means that European clients can now experience HYCM’s full product offering including forex, commodities and equities as well as positioning the 40 year old Group on a renewed growth path as it seeks to extend its global footprint.

HYCM has also announced the introduction of a new logo to reflect these developments which will replace the existing one and will appear on the Group’s website as well as all its advertising and promotional materials from April 2017.

HYCM

Notes to editors:

HYCM is a leading provider of online FX and CFD trading services to retail and institutional investors. With a 40 year operational history and a strong focus on client satisfaction and technological advancement, HYCM has become the online broker of choice for investors across the globe, providing access to a range of asset classes including currencies, commodities, metals, shares and indices.

HYCM offers clients a complete trading solution together with all the trading tools and analysis needed to make informed trading decisions. Backed by its state-of-the-art trading platforms, including the industry leading MetaTrader 4 and mobile app enabling clients to trade while on the go, HYCM has secured a strong industry reputation for delivering a trading experience that is second to none.

HYCM is part of the Henyep Capital Markets Group, an international conglomerate with businesses in financial services, property, education and charity and is regulated by the Financial Conduct Authority of the UK (FCA reference number 186171 and the Cyprus Securities and Exchange Commission (CySEC licence number 259/14).

The company is represented globally with offices in United Kingdom, Hong Kong, Cyprus and Dubai.

Contact:

HYCM
Rosemary Barnes
Email: rosemary.barnes@hycm.com
Telephone: +357 25 24 5750
www.hycm.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing5.2.2026 07:30:00 CET | Press release

Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu Takeuchi) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano, “Sysmex”) have agreed on a sales collaboration for dementia testing. This agreement follows continued discussions based on the Basic Agreement on Business Collaboration in the Field of Immunoassay concluded in October 2023.1 Sysmex will exclusively sell Fujirebio's fully automated Lumipulse® immunoassay systems and dementia-related reagents ("the Products") in regions and countries mutually agreed upon by both companies. Going forward, Fujirebio and Sysmex will collaborate to meet the growing testing needs accompanying the wider adoption of therapeutic drugs and will gradually expand the countries where the Products are sold. Since entering into the Basic Agreement on Business Collaboration in Octob

Invivoscribe® Launches LeukoStrat® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 06:30:00 CET | Press release

Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan

VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 01:00:00 CET | Press release

Enabling Next-Generation High-Performance Automotive Camera Systems VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise

Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 20264.2.2026 22:30:00 CET | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and year after the close of markets on Wednesday, March 4, 2026. CONFERENCE CALL DETAILS DATE: Thursday, March 5, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/567578009 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that

Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 22:30:00 CET | Press release

Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye